Carnegie acted as Sole Global Coordinator and Sole Bookrunner in EIFO’s sale of its entire shareholding in Zealand Pharma.

Carnegie advised Danmarks Eksport- og Investeringsfond (“EIFO”) in the sale of 1,921,466 shares at a price of DKK 260 per share, corresponding to approximately DKK 500m, in Zealand Pharma A/S (“Zealand Pharma”). The shares were sold through an accelerated bookbuilding to Danish and international institutional investors.

Following the sale, EIFO no longer hold any shares in Zealand Pharma.

About EIFO

The Export and Investment Fund of Denmark (EIFO) provides a single point of access for Danish companies as well as for their foreign and domestic business partners who need risk-tolerant government capital. EIFO is the national promotional bank and export credit agency of Denmark combined in one financial institution.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit

Related articles